Steven Cohen Point Biopharma Global Inc. Transaction History

Point72 Asset Management, L.P.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$6.67 - $9.71 $7.6 Million - $11.1 Million	-1,140,067 Reduced 59.1%	789,100 $5.26 Million
Q2 2023 Aug 14, 2023	SELL	$6.86 - $10.86 $8.13 Million - $12.9 Million	-1,185,194 Reduced 38.06%	1,929,167 $17.5 Million
Q1 2023 May 15, 2023	SELL	$6.78 - $8.1 $564,123 - $673,952	-83,204 Reduced 2.6%	3,114,361 $22.6 Million
Q4 2022 Feb 14, 2023	SELL	$5.72 - $9.78 $2.83 Million - $4.84 Million	-495,055 Reduced 13.41%	3,197,565 $23.3 Million
Q3 2022 Nov 14, 2022	BUY	$7.24 - $10.31 $12.6 Million - $17.9 Million	1,738,391 Added 88.96%	3,692,620 $28.5 Million
Q2 2022 Aug 15, 2022	BUY	$5.6 - $9.5 $10.7 Million - $18.2 Million	1,911,961 Added 4523.42%	1,954,229 $13.3 Million
Q1 2022 May 16, 2022	BUY	$5.46 - $8.13 $230,783 - $343,638	42,268 New	42,268 $337,000

20K

Ticker PNT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 104,025,000
Description
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate canc...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.